Analysis for AMGN

📈 Growth & Financial Trajectory

Eight quarters show a steady revenue uptrend from about $8.39B (2024-Q2) to $10.05B (2026-Q2), a ~19.9% increase. Net income grows from about $0.75B to $2.38B, up ~218%. The path includes quarterly bumps but a clear uplift in earnings power, with 2025–2026 periods delivering stronger profitability. Operating cash flow remains robust; investing cash flow is negative as expected, reflecting ongoing capex and portfolio activity.

💰 Margins & Cash Flow

Gross margin averaged around 69%, with pockets in the 70s–80s in select quarters. Operating margins generally run in the 28–41% range, signaling healthy operating leverage. Cash flow from operating activities ranged roughly $1.2B–$4.0B per quarter, while net cash flow from investing activities was negative in most periods and financing activity remained modest.

🛡️ Balance Sheet & Liquidity

Balance sheet remains asset-rich (around $90B–$96B), with liabilities near $80B–$84B and long‑term debt typically in the $56B–$62B band. Equity is modest, producing a lean balance sheet but stable liquidity supported by durable operating cash flow.

⚠️ Key Drivers & Risks

• Drivers: Durable demand for Amgen's biologics and a strong, cash‑generating operating base; ongoing cost discipline and efficient manufacturing.
• Risks: High leverage and interest-rate sensitivity; regulatory/patent/regulatory risks and competitive dynamics.